TIL Therapy Endures for Carefully Selected Patients: A Q&A with Dr. Benjamin C. Creelan
Joy CurzioDr. Benjamin C. Creelan shares his passion for cell therapy research and insights into current data. Read more
Optimal Pathologic Staging of Lung Cancer Depends on More Than the Pathologist
Mary Beth Beasley, MDPathology—and pathologic staging in particular—can be improved through multidisciplinary efforts. Read more
Quality of Life After VATS and SABR for Early-stage Lung Cancer: The Lilac Study
Cecilia Pompili, MD PhD+more
SABR patients were stable during the 12 months while surgical patients reported clinically significant deterioration at 6 weeks. Read more
Early Palliative Care: A European Perspective
Florian Scotté, MD, PhDThe benefits of early palliative care have been proven. Could negative connotations of palliative care be impeding its adoption? Read more
Valuable Intersections: Maximizing Career Opportunities Arising From The Relationship Between Academia and Industry
Jean-Charles Soria, MD, PhDFor Dr. Jean-Charles Soria, the opportunity to make science actionable and increase its impact drove his decision to work in industry. Read more
Association aims to bring attention to the often-overlooked links between air pollution and lung cancer. Read more
Dr. Jhanelle Gray takes the reins as chair of the SWOG Lung Cancer Committee. Keep reading for more about this and other moves in thoracic oncology. Read more
IASLC’s Global Reach a Strength on the Road to a Cure for Lung Cancer
Karen Kelly, MDIn her first letter to ICLN readers, new CEO Karen Kelly discusses keys to achieving the association’s mission. Read more
Tumor Growth Rate as a Guide for Precision Lung Cancer Therapy
Mizuki Nishino, MD, MPH+more
The speed at which a tumor progresses may prove to be a useful tool in therapeutic decision-making. Read more
Patient Perspective: The Promise of Personalized Medicine
Angus Pratt, MBAGrowing treatment options for patients with late-stage lung cancer bring hope—and challenges. Read more